Torrent Pharmaceuticals
- Market Cap
- ₹1,78,374 Cr
- P/E
- 77.80
Key Fundamentals
LargecapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 15.20%
- Debt to Equity
- 0.77
- EPS (TTM)
- ₹60.28
- Book Value
- ₹483.03
- Market Cap
- ₹1,78,374 Cr
- P/E (TTM)
- 77.80
- P/B
- 9.71
- ROE
- 27.40%
- Dividend Yield
- 0.82%
- EBITDA
- ₹4,465 Cr
- 52W High
- ₹5,250.00
- 52W Low
- ₹3,672.30
- Day Range
- ₹4,611.20 – ₹4,689.50
- Volume
- 2,00,042
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| 1,884.90 | 41.25 | 4,52,251 | 5.07 | 0.85% | 16.00% | 20.50% | 61,631 | 10,987 | |
| 11,180.50 | 88.26 | 2,96,807 | 16.49 | 0.27% | 16.50% | 22.00% | 12,191 | 3,363 | |
| 4,689.50 | 77.80 | 1,78,374 | 9.71 | 0.82% | 27.40% | 15.20% | 17,400 | 2,099 | |
| 2,294.60 | 92.52 | 1,23,980 | 20.45 | 0.04% | 18.30% | 17.80% | 7,823 | 1,332 | |
| 1,200.00 | 28.63 | 1,19,700 | 4.30 | 0.08% | 21.20% | 21.10% | 30,378 | 4,303 | |
| 1,390.20 | 41.44 | 1,16,037 | 2.99 | 0.57% | 11.20% | 13.00% | 33,097 | 2,760 | |
| 1,415.00 | 39.45 | 1,14,312 | 3.23 | 0.92% | 11.60% | 15.50% | 28,139 | 2,855 | |
| Median 7 companies | 1,884.90 | 41.44 | 1,23,980 | 5.07 | 0.57% | 16.50% | 17.80% | 28,139 | 2,855 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 73
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 46
- Average
- Cheap vs sector & own history 24% weight
- Growth
- 98
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 15
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 19
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 46
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company is expected to give good quarter
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%
- Company has been maintaining a healthy dividend payout of 57.8%
Weaknesses
3- Stock is trading at 9.71 times its book value
- Promoter holding has decreased over last quarter: -7.53%
- The company has delivered a poor sales growth of 11.8% over past five years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 7 | 7 | 5 |
| Oscillators | Bearish | 2 | 7 | 0 |
| Moving Averages | Neutral | 5 | 0 | 5 |
Oscillators
Bearish
Overall
Bearish
Moving Averages
Neutral
Key readings
- RSI (14)
- 50.46
- Neutral
- MACD (12,26,9)
- −9.79
- Bearish
- SMA (50)
- 4,730.52
- Bearish
- SMA (200)
- 4,564.14
- Bullish
As of
Analyst Rating
23 of 29 analysts rate Buy, 5 Hold, 1 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +7.65% |
|---|---|
| 5Y | +11.80% |
| 3Y | +13.27% |
| 1Y | +21.40% |
| TTM | +42.06% |
Net profit
| 10Y | +2.12% |
|---|---|
| 5Y | +11.30% |
| 3Y | +19.75% |
| 1Y | +11.88% |
| TTM | −1.92% |
Operating cash flow
| 10Y | +0.98% |
|---|---|
| 5Y | +8.56% |
| 3Y | +8.48% |
| 1Y | +16.94% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −8.27 pp |
|---|---|
| 5Y | +1.62 pp |
| 3Y | +3.06 pp |
| 1Y | +0.29 pp |
| TTM | +0.58 pp |
Revenue by year
| Mar 2017 | ₹5,816 Cr |
|---|---|
| Mar 2018 | ₹5,950 Cr |
| Mar 2019 | ₹7,673 Cr |
| Mar 2020 | ₹7,939 Cr |
| Mar 2021 | ₹8,005 Cr |
| Mar 2022 | ₹8,508 Cr |
| Mar 2023 | ₹9,620 Cr |
| Mar 2024 | ₹10,728 Cr |
| Mar 2025 | ₹11,516 Cr |
| Mar 2026 | ₹13,980 Cr |
Net profit by year
| Mar 2017 | ₹934 Cr |
|---|---|
| Mar 2018 | ₹678 Cr |
| Mar 2019 | ₹436 Cr |
| Mar 2020 | ₹1,025 Cr |
| Mar 2021 | ₹1,252 Cr |
| Mar 2022 | ₹777 Cr |
| Mar 2023 | ₹1,245 Cr |
| Mar 2024 | ₹1,656 Cr |
| Mar 2025 | ₹1,911 Cr |
| Mar 2026 | ₹2,138 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Torrent Pharmaceuticals trades at ₹4,691.20 as of 2026-11-16 with a market cap of ₹1,78,438 crore. The company commands a PE of 77.82x and a price-to-book of 9.71x, reflecting premium valuations, while delivering a 3-year ROE of 26% and TTM sales growth of 42%. Debt-to-equity stands at 1.79, and promoter holding declined by 7.53% in the last quarter.
- TTM revenue growth of 42% marks a sharp acceleration compared to the 5-year compounded sales growth of 12%, signalling strong recent top-line momentum
- 3-year ROE of 26% and 5-year ROE of 24% demonstrate consistently high capital efficiency well above industry averages
- Stock price CAGR of 31% over 3 years and 27% over 5 years reflects sustained long-term wealth creation for shareholders
- Healthy dividend payout ratio of 57.8% indicates shareholder-friendly capital allocation, with a current dividend yield of 0.81%
- 3-year compounded profit growth of 22% shows meaningful earnings expansion in the medium term
- Last year ROE of 27% is the highest in the reported range, suggesting improving profitability trends
- The stock trades roughly 11% below its 52-week high of ₹5,250, offering a pullback from peak levels while remaining 28% above the 52-week low of ₹3,672.30
- PE of 77.82x is significantly elevated, demanding sustained high earnings growth to justify the premium valuation
- Debt-to-equity ratio of 1.79 is relatively high for a pharmaceutical company, increasing financial risk and interest burden
- Promoter holding decreased by 7.53% over the last quarter, which may signal reduced insider confidence
- Price-to-book of 9.71x is steep, meaning investors are paying nearly ten times the book value per share
- TTM profit growth of 0% stands in stark contrast to the 42% sales growth, indicating margin compression or one-off cost pressures eroding bottom-line performance
- 10-year compounded profit growth of just 2% suggests long-term earnings have barely kept pace with inflation despite an 8% sales CAGR over the same period
- ROCE of 9.06% is modest relative to ROE of 12.16%, and the gap hints at leverage-driven returns rather than pure operational efficiency
- Potential capitalisation of interest costs may be flattering reported profitability, masking the true cost structure
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: A quiet week for Torrent Pharma with no major catalysts. The ₹3.12 crore GST penalty is minor relative to the company's scale and relates to a legacy JB Chemicals matter under appeal. Scheduled NCD redemption reflects orderly debt management. Near-term direction will likely depend on broader sector sentiment and any updates shared at the upcoming investor meets in mid-November.
- GST penalty on legacy acquisition Nov 5
Torrent Pharma received a ₹3.12 crore GST penalty order from Tiruvallur authorities related to pre-acquisition JB Chemicals matters. The company plans to appeal the order.
- ₹100 Cr NCD redemption on schedule Nov 9
Torrent Pharmaceuticals redeemed ₹100 crore in unlisted secured redeemable non-convertible debentures on November 9, 2026, as per the scheduled repayment timeline.
- Investor conferences in mid-November Nov 6
Torrent Pharma will participate in investor conferences in Mumbai on November 16 and 17, 2026, signaling continued engagement with the institutional investor community.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,660 | 2,732 | 2,745 | 2,859 | 2,889 | 2,809 | 2,959 | 3,178 | 3,302 | 3,303 | 4,197 | 4,921 | 4,979 |
| Expenses | 1,835 | 1,863 | 1,862 | 1,955 | 1,950 | 1,895 | 1,995 | 2,146 | 2,219 | 2,215 | 2,841 | 3,257 | 3,313 |
| Operating Profit | 825 | 869 | 883 | 904 | 939 | 914 | 964 | 1,032 | 1,083 | 1,088 | 1,356 | 1,664 | 1,666 |
| OPM % | 31% | 32% | 32% | 32% | 32% | 33% | 33% | 32% | 33% | 33% | 32% | 34% | 33% |
| Other Income | 26 | −33 | 31 | 24 | −16 | 33 | −18 | −37 | −27 | −23 | −17 | −33 | −10 |
| Interest | 91 | 80 | 80 | 75 | 64 | 57 | 56 | 56 | 48 | 45 | 236 | 305 | 300 |
| Depreciation | 201 | 213 | 203 | 197 | 198 | 199 | 201 | 201 | 204 | 206 | 508 | 593 | 609 |
| Exceptional Items | — | 88 | — | — | — | — | −24 | — | −13 | — | −66 | — | −10 |
| PBT | 559 | 631 | 631 | 656 | 661 | 691 | 665 | 738 | 791 | 814 | 529 | 733 | 737 |
| Tax % | 31% | 30% | 29% | 30% | 31% | 27% | 25% | 26% | 25% | 22% | 31% | 23% | 28% |
| Net Profit | 386 | 443 | 449 | 457 | 453 | 503 | 498 | 548 | 591 | 635 | 364 | 566 | 534 |
| EPS (₹) | 11.41 | 13.09 | 13.27 | 13.50 | 13.38 | 14.86 | 14.71 | 16.19 | 17.46 | 18.76 | 10.76 | 16.72 | 14.04 |
| YoY Sales growth | 16 | 10 | 10 | 10 | 9 | 3 | 8 | 11 | 14 | 18 | 42 | 55 | 51 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,636 | 6,687 | 5,816 | 5,950 | 7,673 | 7,939 | 8,005 | 8,508 | 9,620 | 10,728 | 11,516 | 13,980 | 17,400 |
| Expenses | 3,616 | 3,954 | 4,438 | 4,601 | 5,690 | 5,769 | 5,524 | 6,077 | 6,778 | 7,360 | 7,795 | 9,421 | 11,626 |
| Operating Profit | 1,020 | 2,733 | 1,377 | 1,349 | 1,983 | 2,170 | 2,480 | 2,431 | 2,842 | 3,368 | 3,721 | 4,558 | 5,774 |
| OPM % | 22% | 41% | 24% | 23% | 26% | 27% | 31% | 29% | 30% | 31% | 32% | 33% | 33% |
| Other Income | 286 | 32 | 223 | 299 | 57 | 122 | 57 | 197 | 45 | 58 | 23 | −182 | −159 |
| Interest | 175 | 184 | 206 | 308 | 504 | 451 | 353 | 255 | 333 | 354 | 252 | 385 | 886 |
| Depreciation | 191 | 238 | 307 | 409 | 618 | 654 | 658 | 662 | 707 | 808 | 795 | 1,119 | 1,916 |
| Exceptional Items | — | — | — | — | −357 | — | — | −485 | — | 88 | −24 | — | — |
| PBT | 940 | 2,343 | 1,088 | 931 | 562 | 1,187 | 1,526 | 1,226 | 1,847 | 2,352 | 2,673 | 2,872 | 2,813 |
| Tax % | 20% | 26% | 14% | 27% | 22% | 14% | 18% | 37% | 33% | 30% | 28% | 26% | — |
| Net Profit | 751 | 1,733 | 934 | 678 | 436 | 1,025 | 1,252 | 777 | 1,245 | 1,656 | 1,911 | 2,138 | 2,099 |
| EPS (₹) | 22.19 | 51.22 | 27.59 | 20.04 | 12.89 | 30.28 | 36.99 | 22.97 | 36.79 | 48.94 | 56.47 | 63.92 | 60.28 |
| Div. Payout % | 25% | 34% | 25% | 35% | 66% | 53% | 47% | 105% | 60% | 57% | 57% | 59% | — |
| Sales growth | 11 | 44 | −13 | 2 | 29 | 3 | 1 | 6 | 13 | 12 | 7 | 21 | 42 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 190 |
| Reserves | 2,406 | 3,409 | 4,266 | 4,538 | 4,640 | 4,739 | 5,753 | 5,868 | 6,029 | 6,687 | 7,421 | 8,219 | 18,183 |
| Borrowings | 2,740 | 2,352 | 2,510 | 6,462 | 6,038 | 5,784 | 4,874 | 4,070 | 5,369 | 4,022 | 3,202 | 15,026 | 14,107 |
| Other Liabilities | 2,589 | 3,040 | 2,740 | 3,159 | 3,351 | 3,402 | 3,363 | 2,884 | 3,043 | 3,627 | 3,603 | 20,200 | 12,135 |
| Total Liabilities | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 14,396 | 43,614 | 44,615 |
| Fixed Assets | 2,833 | 2,859 | 3,688 | 7,855 | 7,748 | 7,533 | 7,065 | 6,423 | 8,121 | 8,138 | 7,947 | 33,191 | 32,621 |
| CWIP | 678 | 1,042 | 519 | 647 | 617 | 712 | 889 | 630 | 765 | 361 | 478 | 641 | 404 |
| Investments | 298 | 780 | 804 | 492 | 353 | 2 | 181 | 226 | 199 | 173 | 156 | 948 | 2,160 |
| Other Assets | 4,011 | 4,206 | 4,589 | 5,249 | 5,395 | 5,763 | 5,940 | 5,628 | 5,524 | 5,834 | 5,815 | 8,833 | 9,430 |
| Total Assets | 7,820 | 8,886 | 9,601 | 14,243 | 14,113 | 14,010 | 14,075 | 12,906 | 14,610 | 14,505 | 14,396 | 43,614 | 44,615 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 810 | 2,742 | 1,009 | 894 | 1,798 | 1,393 | 2,005 | 1,803 | 2,368 | 3,266 | 2,585 | 3,023 |
| Investing | −2,113 | −869 | −798 | −4,677 | −246 | 229 | −444 | −196 | −2,335 | −160 | −549 | −12,630 |
| Financing | 1,212 | −1,435 | −193 | 3,417 | −1,314 | −1,549 | −1,651 | −1,781 | 77 | −2,780 | −2,298 | 10,151 |
| Net Cash Flow | −90 | 437 | 18 | −366 | 238 | 73 | −89 | −174 | 110 | 327 | −262 | 544 |
| Free Cash Flow | 574 | 2,150 | 523 | 105 | 1,138 | 990 | 1,671 | 1,607 | 1,953 | 2,967 | 1,991 | 2,386 |
| CFO/EBITDA | 85 | 121 | 101 | 87 | 105 | 77 | 88 | 91 | 97 | 112 | 86 | 84 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 125 | 79 | 60 | 77 | 68 | 76 | 69 | 70 | 74 | 63 | 59 | 79 |
| Inventory Days | 275 | 314 | 318 | 429 | 318 | 362 | 456 | 368 | 298 | 310 | 334 | 338 |
| Days Payable | 472 | 523 | 356 | 447 | 345 | 345 | 351 | 250 | 224 | 284 | 239 | 254 |
| Cash Conversion Cycle | −71 | −130 | 21 | 59 | 42 | 93 | 174 | 188 | 147 | 89 | 154 | 163 |
| Working Capital Days | 29 | −1 | 28 | −80 | −62 | −52 | −5 | 7 | −33 | −27 | 7 | −26 |
| ROCE % | 27% | 48% | 19% | 13% | 13% | 15% | 17% | 19% | 20% | 23% | 27% | 15% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Torrent Pharmaceuticals insights
70 extracted metrics across FY12–FY27.
Documents
- Q2 FY27 concall · Oct 2026Transcript Recording
- Q1 FY27 concall · Jul 2026Transcript
- Q4 FY26 concall · May 2026Transcript Recording
- Q3 FY26 concall · Feb 2026Transcript Recording
- Q2 FY26 concall · Nov 2025Transcript PPT Recording
- 30 Jul 2026
- 22 May 2026
- 13 Feb 2026
- 7 Oct 2026
- 21 Jul 2026
- 5 Jan 2026
- 2 Jan 2026
- 6 Oct 2025
- General announcements 6 Nov 2026
Frequently Asked Questions about Torrent Pharmaceuticals
What does Torrent Pharmaceuticals Ltd do?
Where is Torrent Pharmaceuticals Ltd (TORNTPHARM) listed?
Which sector does Torrent Pharmaceuticals Ltd belong to?
What is the market capitalisation of Torrent Pharmaceuticals Ltd?
What is the PE ratio of Torrent Pharmaceuticals Ltd?
What is the 52-week high and low of Torrent Pharmaceuticals Ltd?
Does Torrent Pharmaceuticals Ltd pay dividends?
What is the Return on Equity (ROE) of Torrent Pharmaceuticals Ltd?
Company Information
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/TORNTPHARM.md for Torrent Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.